TC BioPharm To Begin Proof Of Concept Preclinical Studies For Lead Therapy TCB008 To Treat Monkeypox; Aims To Partner With Infectious Disease Center For Rapid Advancement Of Studies
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm is set to begin preclinical studies for its lead therapy TCB008 aimed at treating monkeypox. The company plans to collaborate with an infectious disease center to expedite these studies.
September 06, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TC BioPharm is initiating preclinical studies for TCB008, targeting monkeypox treatment. The company seeks a partnership with an infectious disease center to accelerate these studies.
The initiation of preclinical studies for TCB008 and the potential partnership with an infectious disease center are positive developments for TC BioPharm. These steps could lead to advancements in monkeypox treatment, potentially boosting investor confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100